http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20190064215-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aea5ddac9cae108a5f80101c3f50a351 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-284 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28 |
| filingDate | 2017-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fec032ddd385c450749b1944c78ca4e8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e0df34684e75368b2a4c394a8c645310 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5699bca81e595287115b8cfb698dc565 |
| publicationDate | 2019-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20190064215-A |
| titleOfInvention | Pharmaceutical Composition Comprising Tofacitinib |
| abstract | The present invention relates to a core comprising topad Citinib or a pharmaceutically acceptable salt thereof; And a coating layer containing a water-insoluble coating agent and a water-soluble coating agent on the core. The present invention provides a pharmaceutical composition that inhibits the initial release of topocitinib and provides a pharmaceutical composition with an early lag time and is capable of maintaining the effective blood level of topafi- to provide. In addition, the present invention provides a pharmaceutical composition having excellent content uniformity, solubility, stability, and bioavailability of topasidinib. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021038014-A1 |
| priorityDate | 2017-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 70.